Literature DB >> 16300921

The role of axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases.

M Gipponi1, G Canavese, R Lionetto, A Catturich, C Vecchio, A Sapino, D Friedman, F Cafiero.   

Abstract

AIM: To identify by means of clinical and histopathological features a subset of breast cancer patients with sentinel lymph-node (sN) micrometastases and metastatic disease confined only to the sN in order to spare them an unnecessary axillary lymph node dissection (ALND).
MATERIALS AND METHODS: From January 1998 to December 2004, 116 patients with sN micrometastases underwent standard ALND for early-stage (T1-2 N0 M0) invasive breast cancer; clinical and histopathologic parameters were prospectively collected and evaluated by means of univariate and logistic regression analysis in order to identify which patients with sN micrometastases were free of metastasis in axillary non-sN.
RESULTS: Sixteen of 116 patients with sN micrometastases had tumour involvement of non-sN, with six and 10 patients having non-sN micrometastases and macrometastases, respectively. None of 19 patients with primary tumour measuring </= 10 mm had tumour-positive non-sN; moreover, none of 15 patients with G1 tumours had non-sN metastases. The mean tumour size in patients with non-sN involvement was 21.3 mm (range, 12-40 mm). Univariate test of association between clinical and histopathologic features and non-sN status showed that the primary tumour size (P=0.005) and the presence of lymphovascular invasion (P=0.000) were the only significant predictors of non-sN involvement. By logistic regression, primary tumour size (P=0.011), lymphovascular invasion (P=0.001), and size of sN micrometastases were the only variables remaining into the model, although the latter parameter was not statistically significant.
CONCLUSIONS: In patients with sN micrometastases, primary tumour size and lymphovascular invasion significantly predict non-sN status; notably, no patient with T1a-T1b and/or G1 tumours had non-sN metastases so that they could be spared an unnecessary ALND.

Entities:  

Mesh:

Year:  2005        PMID: 16300921     DOI: 10.1016/j.ejso.2005.10.003

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Sentinel lymph node micrometastases and isolated tumor cells in breast cancer: an evolving field.

Authors:  Fang Fan
Journal:  Gland Surg       Date:  2012-05

2.  Axillary Lymph Node Status in Early-Stage Breast Cancer Patients with Sentinel Node Micrometastases (0.2-2 mm).

Authors:  Johannes Bargehr; Michael Edlinger; Michael Hubalek; Christian Marth; Roland Reitsamer
Journal:  Breast Care (Basel)       Date:  2013-06       Impact factor: 2.860

Review 3.  Clinical evidence of breast cancer micrometastasis in the era of sentinel node biopsy.

Authors:  Noriaki Wada; Shigeru Imoto
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

4.  Therapeutic effect of cisplatin given with a lymphatic drug delivery system on false-negative metastatic lymph nodes.

Authors:  Asuka Tada; Sachiko Horie; Shiro Mori; Tetsuya Kodama
Journal:  Cancer Sci       Date:  2017-09-15       Impact factor: 6.716

5.  Technical limits of comparison of step-sectioning,immunohistochemistry and RT-PCR on breast cancer sentinel nodes: a study on methacarn-fixed tissue.

Authors:  Lorenzo Daniele; Laura Annaratone; Elena Allia; Sara Mariani; Enrico Armando; Martino Bosco; Luigia Macrì; Paola Cassoni; Giuseppe D'Armento; Gianni Bussolati; Gabor Cserni; Anna Sapino
Journal:  J Cell Mol Med       Date:  2008-07-30       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.